DDInter1220 DDInter105
Milnacipran is a selective serotonin and norepinephrine reuptake inhibitor (SNRI) and like many agents in this category was originally developed for and continues to be approved and indicated for the treatment of depression [F3928, F3934, A175786, A175951]. Furthermore, in 2009 the US FDA approved milnacipran for the additional indication of treating fibromyalgia, although other regional regulatory authorities like the EMA, among others, have not yet approved the agent for such treatment, citing lack of robust evidence of efficacy, insufficient demonstration of maintenance of effect, and other concerns [F3928, F3934]. Nevertheless, milnacipran demonstrates a somewhat unique characteristic among SNRIs to elicit a relatively balanced reuptake inhibition of both serotonin and noradrenaline, with a somewhat increased preference for noradrenaline reuptake inhibition - which is potentially a point of interest given the plausible
A plasma alpha 2 glycoprotein that accounts for the major antithrombin activity of normal plasma and also inhibits several other enzymes. It is a member of the serpin superfamily.
Milnacipran {u} (Compound) resembles {v} (Compound) Levomilnacipran
Milnacipran {u} (Compound) resembles {v} (Compound) Meperidine
Milnacipran {u} (Compound) binds {v} (Gene) SLC6A4
Milnacipran {u} (Compound) is included by {v} (Pharmacologic Class) Norepinephrine Uptake Inhibitors
Milnacipran {u} (Compound) downregulates {v} (Gene) GJA1
Milnacipran {u} (Compound) causes {v} (Side Effect) Migraine
Milnacipran {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Cyproheptadine
Milnacipran {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Acalabrutinib
Milnacipran {u} may lead to a major life threatening interaction when taken with {v} Phentermine
Milnacipran {u} may lead to a major life threatening interaction when taken with {v} Teriflunomide
Milnacipran (Compound) resembles Levomilnacipran (Compound)
Milnacipran (Compound) resembles Meperidine (Compound)
Milnacipran (Compound) binds SLC6A4 (Gene)
Milnacipran (Compound) is included by Norepinephrine Uptake Inhibitors (Pharmacologic Class)
Milnacipran (Compound) downregulates GJA1 (Gene)
Milnacipran (Compound) causes Migraine (Side Effect)
Milnacipran may cause a moderate interaction that could exacerbate diseases when taken with Cyproheptadine
Milnacipran may cause a moderate interaction that could exacerbate diseases when taken with Acalabrutinib
Milnacipran may lead to a major life threatening interaction when taken with Phentermine
Milnacipran may lead to a major life threatening interaction when taken with Teriflunomide